University of California Los Angeles
Los Angeles, California, 90095, United States
Location status: Recruiting
NCT Number: NCT05190978
Surgical mesh products, particularly acellular dermal matrices (ADM), are now used by the majority of plastic surgeons to assist with the nearly 100,000 prosthetic breast reconstruction procedures in the United States, despite never being approved by Food and Drug Administration (FDA) for this indication. As surgeons transition to placing breast implants above the chest muscle (pre-pectoral), there has been an increasing reliance on these often expensive mesh products without robust evidence to understand their risks and benefits. Our pilot study is a randomized multi-center trial to evaluate surgical mesh assistance in pre-pectoral tissue expander to breast implant reconstruction to address vital questions for women's public health.
Interested in participating?
Request Info22 year–75 year
Female
Interventional
Not applicable
Los Angeles, California, 90095, United States
Location status: Recruiting
One in eight women will develop breast cancer in her lifetime, causing both physical and psychological trauma due to invasive treatments and the distress associated with removal of a breast. Breast reconstruction after mastectomy has become a critical procedure for many women to restore psychological wellbeing, with implant-based reconstruction the most common approach. Nearly 100,000 patients undergo reconstruction with implants every year in the United States.
Surgical mesh devices, particularly acellular dermal matrices, are now used off-label by most reconstructive surgeons performing prosthetic breast reconstruction. In the past decade, surgeons have advocated a transition from submuscular reconstruction (placement of the implant under the pectoralis muscle) to pre-pectoral (placement above the pectoralis) and often consider mesh to be necessary for this procedure. Surgical mesh has not been approved by the FDA for breast reconstruction for either anatomic location. These mesh devices are considered Class III medical devices and FDA recently prioritized the evaluation of these products during a panel meeting in 2019.
No Level I randomized trial has been successfully performed to determine the actual risks and benefits of mesh devices in breast reconstruction. This study proposes a pilot study as the first ever randomized, multi-center trial for mesh assistance in two-stage prosthetic pre-pectoral breast reconstruction, across the major manufacturers. The goals are to demonstrate feasibility of such a study and to generate high level data toward the evaluation of safety and effectiveness of these products for the benefit of women's public health
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Acellular dermal matrix will surgically implanted around the tissue expanders in patients in the ADM cohort.
Acellular dermal matrix will not be surgically implanted around the tissue expanders in patients in the control cohort.
Time frame: 2 years
Relative rate of major complications (requiring unplanned re-admission or re-operation)
Time frame: 2 years
BREAST-Q validated patient reported questionnaire to assess results of final reconstruction.
Time frame: 2 years
Time from expander placement to implant exchange
Time frame: 2 years
Individual complication rates
Time frame: 2 years
Rate of capsular contracture
Interested in participating?
Request InfoUniversity of California, Los Angeles
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07547774
Breast Cancer, Breast Diseases
Ankara, Yenimahalle, Turkey (Türkiye)
View Trial DetailsNCT07245069
Anthracycline-induced Cardiac Toxicity, Arterial Stiffness
Ljubljana, Slovenia
View Trial DetailsNCT05620329
Breast Cancer, Breast Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT06553235
Breast Cancer, Breast Diseases
Aarhus N, Denmark
View Trial Details